Hematology/Oncology

Top Story

Eliminating pretreatment biopsy reduced cost without compromising care for BCC

September 4, 2015

A simplified detect-and-treat scheme that eliminates the biopsy before initiating treatment of basal cell carcinoma resulted in cost savings while maintaining quality of care, according to recently published study results.

Researchers developed a decision analytic model to compare costs of traditional basal cell carcinoma (BCC) management, which involved pretreatment biopsy in all cases, and a detect-and-treat scheme, in which patients presenting with well-delineated and unequivocal BCC lesions were offered shave removal or referred to a Mohs micrographic surgeon, who conducted an on-site histologic check. Literature and institutional data analysis were used to determine values for model parameters, and a 2014 Medicare fee schedule was used to estimate costs.

In the Journals

Immune perturbations may increase melanoma risk among certain non-Hodgkin's lymphoma survivors

September 4, 2015
Certain chemotherapeutic agents and immune-related medical conditions appeared to contribute to increased melanoma risk among older survivors of a specific…
FDA News

FDA grants breakthrough therapy designation to ACE910 for hemophilia A

September 4, 2015
The FDA granted breakthrough therapy designation to ACE910 for the prophylactic treatment of patients aged at least 12 years who have hemophilia A with factor VIII…
In the JournalsPerspective

Advanced care planning rates increase modestly among patients with cancer

September 4, 2015
The use of advanced care planning among patients with cancer increased modestly between 2000 and 2012, according to an analysis of prospectively collected survey data.A…

New ACA rule aims to protect patients from sex, disability discrimination

September 4, 2015
The HHS has announced a proposed rule to modify discrimination provisions of the Affordable Care Act, which would help provide equal access to health care and coverage…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Pancreatic Cancer

No commercial support for this activity.

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
morganatic-roan
morganatic-roan